Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Genitourinary Cancers
•
Medical Oncology
•
Supportive Care
Do you get DEXA scans routinely before starting ADT for prostate cancer or endocrine therapy for breast cancer?
Does your practice differ in the adjuvant/definitive setting versus the metastatic setting?
Related Questions
What are your top takeaways in Breast Cancer from ESMO 2025?
When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?